


Schematic View of JFTC review (Tentative Translation)

For reference

Acquisition

Acquisition by M3 of shares in Nihon Ultmarc



The JFTC conducted investigation into the Acquisition because of its concerns about restraint of competition, although it did not meet the notification criteria, and found that the Acquisition would substantially restrain competition through (i), (ii) and (iii).

Proposal for Remedies by the Parties

- ◆ Prohibition of refusal to provide data on doctors and other healthcare professionals, discriminatory treatment and Combined Provision, etc.
- ◆ Implementation of measures to interrupt information flow

The JFTC concluded, on the premise that the Parties will implement the Remedies, that the Acquisition would not substantially restrain competition.